Recent Updates — ZEOX

Zeo ScientifiX announced that its manufacturing facility has become the inaugural recipient of the Association for the Advancement of Blood & Biotherapies (AABB) newly established Quality Management Systems (QMS) Certification. The company received formal notification of this distinction on October 23, 2026, following an independent assessment. This certification validates the company's quality management systems and operational discipline in manufacturing cellular products. Zeo ScientifiX is a U.S. biopharmaceutical company integrating regenerative biologics research, development, and manufacturing with established commercial operations.

Zeo ScientifiX, Inc. entered into a definitive strategic agreement with Pluri Inc. to expand its U.S. manufacturing and commercialization platform in the regenerative medicine, aesthetics, wellness, and longevity markets. Under the terms of the partnership, ZEO will receive an exclusive license to Pluri’s proprietary 3D cell expansion technology for present and future products. In exchange, ZEO will issue shares resulting in Pluri holding a 41% equity stake at closing, with total ownership reaching 50% after additional share issuances and warrant exercises. The transaction includes the creation of Series D Non-Convertible Preferred Stock granting Pluri significant voting control and board representation. Closing is expected in the fourth quarter of 2026, subject to customary conditions. Zeo ScientifiX operates in the biotechnology sector, focusing on biologics manufacturing and commercialization.

Zeo ScientifiX and Pluri Inc. entered into a definitive strategic agreement under which Pluri will issue shares representing 50% of ZEO's issued and outstanding common stock immediately following closing. The transaction combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales infrastructure. Pluri gains exclusive U.S. rights to its CellaV aesthetic product line through the partnership. Following closing, ZEO’s financial results are expected to be consolidated into Pluri’s statements. The deal is not subject to stockholder approval and is expected to close in the fourth quarter of 2026, pending customary conditions including ancillary agreements and regulatory approvals. Zeo ScientifiX operates as a biopharmaceutical company integrating regenerative biologics research, development, and manufacturing with commercial operations.